Fig 1.
Literature search and selection.
Table 1.
Clinical characteristics of included trials.
Table 2.
Results of direct comparisons.
Fig 2.
Network of eligible comparisons.
The size of the nodes is proportional to the number of patients (in parentheses) randomized to receive the treatment. The width of the lines is proportional to the number of trials (beside the line) comparing the connected treatments. TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.
Table 3.
Results of network meta-analysis.
Fig 3.
The treatment rankings based on SUCRA.
(a) progression-free survival; (b) overall survival; (c) serious adverse events. SUCRA, surface under the cumulative ranking curves; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.
Fig 4.
Ranking plot based simultaneously on efficacy (x-axis: SUCRA value of overall survival) and tolerability (y-axis: 1-SUCRA value of serious adverse events).
SUCRA, surface under the cumulative ranking curves; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.